抄録
Bone pain is a most common and devastating complication associated with bone diseases such as osteoporosis, bone metastasis and rheumatoid arthritis. Thus, control of bone pain is a major goal in the management of these bone diseases. In bone destructive cancer, opioids are first-line therapy but palliative, unsatisfactory and inadequate. Inhibitors of osteoclasts including bisphosphonates and denosumab incompletely reduce bone pain, indicating that not only osteoclast-dependent but also osteoclast-independent mechanisms are operant. In this review, we introduce the recent study including ours, targeting the cancer cell and osteoclast created-acidic extracellular microenvironment for Cancer-associated Bone Pain (CABP).
